Warming "Cold" Melanoma with TLR9 Agonists

According to data from two ongoing phase I studies for patients with metastatic melanoma whose disease is refractory to PD-1 blockade, the addition of either CMP-001 or SD-101-both investigational TLR9 agonists-could help reverse this resistance.